MDNC 10-K & 10-Q changes, risk factors and insider trading

You should carefully consider the risks described below together with all of the other information included in this Annual Report before making an investment decision with regard to our securities. The statements contained in or incorporated herein that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, you may lose all or part of your investment. In addition to other information in this registration statement and in other filings we make with the Securities and Exchange Commission, the following risk factors should be carefully considered in evaluating our business as they may have a significant impact on our business, operating results and financial condition. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered as a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods.

The following is a condensed summary of the principal risks associated with our business. These risks represent the key challenges and uncertainties we face, and they are described in greater detail in the “Risk Factors” section of this report. Investing in our securities involves a high degree of risk, and the occurrence of any of these factors could materially and adversely affect our business, financial condition, results of operations, or stock price.

Financial Risks: We carry substantial debt, may need additional financing, and face exposure to interest rate changes, accounting rule shifts, and tax regulation updates, all of which could impact financial flexibility and results.

Operational Challenges: Our success depends on product development, supply chain continuity, and competitive positioning. Industry consolidation, pricing pressures, IT disruptions, and foreign exchange volatility pose risks to our operations and profitability.

Customer and Market Exposure: We rely heavily on a limited number of customers, including DISA Life Sciences, which increases the risk of revenue concentration. Inadequate insurance coverage and internal control weaknesses may further exacerbate operational vulnerabilities.

Management and Governance: Our business depends on a small number of key personnel, many of whom are located outside the U.S. Concentrated voting power among founders and limited public-company experience heighten governance and compliance risks.

Regulatory and Legal: Delays in obtaining regulatory approvals, potential product liability, compliance with marketing and reimbursement rules, IP protection, and evolving environmental and data privacy laws all pose significant risks. Violations could lead to penalties or legal action.

Geopolitical and Regional Risks: Political and economic instability in South Africa—such as load-shedding, exchange controls, and FATF grey-listing—may impair operations. Broader geopolitical tensions and trade disputes also affect supply chains and market access. Geopolitical and trade risks due to tariffs and trade wars.

Market and Securities Risks: Our shares trade on the OTCQX market and are considered penny stocks, which may limit liquidity. Future equity issuances could dilute existing shareholders, and share prices may fluctuate significantly due to external factors Details of the above risks are as follows:

Risks Related to Our Business Operations

Risks Related to Management, Personnel and Control Persons

Risk Associated with Legal and Regulatory Matters

Risks Associated with Political Instability and Regional Issues

Risks Relating to Our Securities

Risks Related to our Financial Position and Need for Capital

As of February 28, 2025, the consolidated Medinotec Group of Companies had approximately $1,505,047 of current liability obligations and $1,033,097 of long-term liabilities outstanding.

The long-term debt relates to the non-current portion of the operating lease liability, deferred tax liabilities as well as an unsecured loan from the related party Minoan Medical, which was the prior shareholder of DISA Medinotec Proprietary Limited. The Medinotec Group of Companies has a period of 3 years post the Initial Public Offer ("IPO”) date of 31 March 2023 to repay the loan, during these 3 years the loan will carry interest at the prevailing prime lending rate of the time. The prevailing prime lending rate as of February 28, 2025, in South Africa is 11.00%.

The interest charged for the year ended February 28, 2025, for the consolidated Medinotec Group of Companies was $176,416 and a 1% movement in the interest rates constitutes a value of $16,038 on an annual basis.

From time to time the Group utilized trade finance to assist with funding of orders for raw materials with longer lead and shipping times the interest spent on trade finance for the year ended February 28, 2025 for the consolidated Medinotec Group of Companies was $28,126 and $35,317 for the year ended February 29, 2024. Trade Finance carries a charge of prime plus 1% therefore 12.00%, at February 28, 2025. A 1% movement in the interest rate would equate to $2,344 for the year ending February 28, 2025. Trade finance is use specific and linked to inventory ordering therefore no forecast will be disclosed for an expected change in annual utilization and the quarter and six-month sensitivity adjustments are disclosed on the current orders financed by trade finance at the time.

As of February 28, 2025, the related party loan for the consolidated Medinotec Group of Companies had a balance of $940,277 with an interest charge of $141,748 per annum at the prevailing prime interest rate of 11.00% at that date. A 1% movement in the interest rates constitutes a value of $12,886.

The Medinotec Group of Companies has the option to settle earlier, and settlement can be in cash or any form of equivalent. It is currently the intention of management to settle the loan in equity at some point in the future, since the agreement allows the Medinotec Group Companies to settle the amounts either in equity or in cash. If equity is used, the impact on cashflow would be zero.

If we elect to settle the loan in cash: Cash reserves available in February 2025 in the Consolidated Medinotec Group of Companies were $2,769,686 and the loan account outstanding at the same time was $940,277. Therefore, if settled today it would constitute 34% of available cash.

The interest rate chargeable is a guideline determined by the South African Reserve Bank and gets utilized by financial institutions to determine the financial gain they may derive from a loan. The Prime rate is therefore at arm’s length and justifiable rate that can be applied to a loan within the borders of the Republic of South Africa.

The Medinotec Group of Companies may need additional financing – any limitation on our ability to obtain such additional financing could have a material adverse effect on the business, financial condition, and results of operations.

Our expansion plans may require additional capital and we may need capital to operate our business in response to circumstances caused by the risks in conducting business in this industry. The raising of additional capital could result in dilution to stockholders. In addition, there is no assurance that we will be able to obtain additional capital if we need it, or that if available, it will be available to us on favorable or reasonable terms. Any limitation on our ability to obtain additional capital as and when needed could have a material adverse effect on the business, financial condition and results of operations.

If third-party payer payment approval cannot be obtained by patients, sales of finished medical devices that include our components may decline significantly and our customers may reduce or eliminate purchases of these components.

The cost-containment measures that healthcare providers are instituting, both in the US and outside of the US could harm our ability to operate profitably.

For the fiscal year ended February 28, 2025, the Consolidated Medinotec Group of Companies reported revenue of $9,113,607, an increase of $4,093,216 or 81.5% compared to $5,020,391 in the prior year. This growth was primarily driven by the full-year impact of newly established distribution agreements, the initial commercialization of a key product in the U.S. market, and continued expansion of our global sales footprint.

Key Drivers of Revenue Growth

For the fiscal year ended February 28, 2025, the Consolidated Medinotec Group of Companies recorded cost of goods sold (COGS) of $4,252,821, compared to $2,577,922 for the year ended February 29, 2024. This represents a year-over-year increase of $1,674,899, in line with the significant growth in sales.

Gross profit for fiscal 2025 was $4,860,786, representing a gross margin of 53%, compared to a gross margin of 49% in fiscal 2024. The increase in gross margin is primarily attributable to increased sales, together with manufacturing and sales processes becoming more efficient as time progresses, as well as an improved sales mix favoring higher-margin products. The effect of exchange rate differences on imports and exports were also more stable during the year.

• Stabilization of Exchange Rates: The Group is exposed to foreign exchange fluctuations related to both imports and exports, which can materially affect margins due to timing differences between procurement and sales. During fiscal 2025, exchange rates remained relatively stable, with the South African Rand appreciating by approximately 4.6% against the U.S. Dollar. This stability helped mitigate currency-related margin volatility.

Related Party Transactions

For the fiscal year ended February 28, 2025, operating expenses totaled $1,669,287, a decrease from $1,841,891 for the fiscal year ended February 29, 2024. This decrease was primarily due to reclassification adjustments, offsetting the increased costs related to business expansion and product rollout.

General and Administrative Expenses: General and administrative (G&A) expenses decreased significantly, although this was partially due to the reclassification of $327,950 in expenses to revenue in the first quarter of fiscal 2025, relating to activities outside the United States. Excluding this reclassification, G&A expenses increased by $48,036, mainly driven by the addition of payroll costs related to new distribution agreements and higher compliance costs as the Company expanded its market presence.

Research and Development (R&D): The Company recorded R&D expenses of $91,133 for the year ended February 28, 2025, up from $22,351 in the prior year. However, R&D spending remains a relatively small portion of our overall operating expenses. This increase was primarily focused on perfecting existing manufacturing processes to support the scaling of our Trachealator product and other potential product integrations. Given the nature of our operations, the majority of our R&D efforts are directed toward refining production methods and ensuring that products can be efficiently manufactured within our current infrastructure. We only engage in R&D for products where a working prototype and proof of concept are already in hand, and we focus exclusively on products that align with our existing capabilities. This approach significantly reduces our R&D costs compared to companies engaged in speculative or early-stage development.

Compliance Costs: A substantial portion of our operating expenses relates to compliance activities required to maintain international standards, including ISO certifications and CE/FDA product registrations. These compliance costs are essential for ensuring that our products meet regulatory requirements in the markets where we operate. Additionally, we incur costs for maintaining distribution licenses and product registrations with local health authorities in each country, such as the South African Health Products Regulatory Authority (SAHPRA) in South Africa. While some of these compliance costs are one-time in nature, many will be recurring as the Company enters new territories and ensures ongoing regulatory compliance. As we expand into more markets, particularly within the medical device industry, these compliance costs will likely increase.

Looking forward, we anticipate that future operating expenses will grow primarily in two areas:

In addition, while R&D expenses will remain relatively modest, the Company's focus will remain on optimizing manufacturing processes, ensuring that production capabilities are aligned with increased product demand and the scalability of our operations.

Non-operating income and expenses for the fiscal year ended February 28, 2025, primarily consist of interest earned on free cash and the management of liquid assets. These amounts are immaterial relative to our core operating results and do not significantly affect the business’s overall financial performance. However, there were some key non-operating transactions that impacted both the balance sheet and income statement during the prior fiscal year.

Note Receivable

On November 30, 2023, the Company fully impaired its note receivable from Innovative Outcomes, which amounted to $642,012. This decision was made prudently, as the receivable was no longer supported by any ongoing Trachealator revenue streams. While the receivable was impaired, it does not eliminate the future liability of Innovative Outcomes to repay the amount. No interest income is recognized on the note while it remains impaired. The full recoverability of the receivable has not yet been definitively tested.

Interest Expense

Interest expense primarily relates to the interest on the related party loan of $141,748 and the interest paid to our logistics service provider of $28,126. These expenses are recorded in line with the terms of the respective agreements and are consistent with prior periods.

Interest Income

Interest income for the fiscal year was earned from two main sources: the note receivable which was impaired and a tax refund receivable. No interest income is recognized on the impaired note receivable, although interest continues to accrue contractually in accordance with the terms of the agreement, while interest on the tax refund receivable was earned during the prior fiscal year, contributing to the total interest income recognized. During the fiscal year ended February 28, 2025, no interest was recognized in respect of the note receivable; while an amount of $8,668 was earned on tax refund receivable, representing a total of $8,668 interest income for the year.

This increase in net income is primarily driven by the higher sales generated from the new cardiology distribution business in South Africa, as well as the increased sales of the Trachealator, an internally designed and manufactured product, in the United States. The growth in both distribution revenues and the Trachealator's success in new markets were key factors in driving this positive shift in profitability.

As of February 28, 2025, the Company had total current assets of $6,423,186 and total assets of $6,808,973. Total current liabilities as of February 28, 2025, were $1,505,047. The Company had working capital of $4,918,139 as of February 28, 2025. In comparison, as of February 29, 2024, the Company had total current assets of $4,379,297 and total assets of $4,804,279. Total current liabilities as of February 29, 2024, were $827,453. Consolidated, we had working capital of $3,551,844 as of February 29, 2024.

Net cash provided by operating activities from continuing operations increased significantly for the fiscal year ended February 28, 2025. This improvement was primarily due to a $2,564,161 increase in profitability, with the Group reporting net income of $2,159,473, compared to a net loss of $404,688 in the prior year. This turnaround was mainly driven by strong growth in distribution revenue, particularly from the launch of the cardiology distribution business in South Africa and expanded U.S. sales of the Trachealator product.

Operational cash flow also benefited from improved working capital management, including better receivables collection and inventory optimization. Operating expenses were carefully controlled, allowing the Group to support growth initiatives—especially in sales and marketing—while maintaining positive cash generation from operations. Management also notes customer concentration risk, with most customers situated within the South African segment, which should be considered in assessing the quality and stability of these cash flows.

Net cash used in investing activities increased for the fiscal year ended February 28, 2025. This change was primarily driven by the absence of inflows from a note receivable, which had generated positive cash flows through repayments in the prior year. In contrast, during the current year, the outstanding balance of the note receivable increased and was subsequently impaired, resulting in no corresponding cash inflow.

Additionally, the Group increased its investment in property, plant, and equipment (PP&E), reflecting continued expansion and operational scaling. These capital expenditures contributed to higher cash outflows from investing activities compared to the prior year.

Our business faces many risks, a number of which are described in the section captioned “Risk Factors” in our Annual Report for the year ended February 28, 2025, filed with the SEC on May 29, 2025, in our Quarterly Report on Form 10-Q for the quarter ended May 31, 2025, filed with the SEC on July 16, 2025, and in our Quarterly Report on From 10-Q for the quarter ended August 31, 2025, filed with the SEC on October 8, 2025. The risks described in our Annual Report and Quarterly Report may not be the only risks we face. Other risks of which we are not yet aware, or that we currently believe are not material, may also materially and adversely impact our business operations or financial results. If any of the events or circumstances described in the risk factors contained in our Annual Report or Quarterly Report occur, our business, financial condition or results of operations could be adversely impacted and the value of an investment in our securities could decline. Investors and prospective investors should consider the risks described in our Annual Report and Quarterly Report, and the information contained below and in the section captioned “Forward-Looking Statements” and elsewhere in this Quarterly Report before deciding whether to invest in our securities.

Risks Related to Our Potential Uplisting to a National Securities Exchange

We may be unable to uplist our common stock to a national securities exchange, or maintain such a listing if achieved, which could adversely affect the liquidity and price of our common stock.

We intend to pursue an uplisting of our common stock to a national securities exchange, such as the Nasdaq Capital Market. However, there can be no assurance that we will meet the initial listing requirements, which include minimum thresholds for stockholders' equity, market value of unrestricted publicly held shares, bid price, number of round lot holders, and other quantitative and qualitative criteria. Recent changes to Nasdaq rules have increased emphasis on sustained pre-listing liquidity and public float for companies uplisting from OTC markets. Even if we qualify initially, we may fail to maintain continued listing standards, resulting in delisting. Failure to achieve or maintain an uplisting could limit investor interest, reduce share liquidity, hinder capital raising, and negatively impact our stock price and overall valuation.

We may require additional capital to meet uplisting requirements or support ongoing operations, and any financing could be dilutive, on unfavorable terms, or unavailable.

Our current cash position and operating cash flows may not be sufficient for long-term needs, including costs related to a potential uplisting (such as audits, legal fees, and governance enhancements). We may seek additional funding through public or private offerings of equity or debt securities. Any equity issuance would dilute existing shareholders. Debt financing could involve restrictive covenants or high interest. There can be no assurance that financing will be available when needed, on acceptable terms, or at all. Failure to raise capital could delay or prevent an uplisting and limit growth initiatives.

Efforts to achieve an uplisting, such as financings or corporate actions, could cause stock price volatility or other adverse effects.

To meet liquidity or other requirements, we may pursue capital raises, potentially at a discount, or other measures. Private financings may involve restrictions on shares that delay their contribution to our public float. These actions could temporarily affect our stock price or shareholder rights.

Risks Related to International Geopolitical Conditions

Geopolitical instability, labor unrest, and economic disruptions in certain foreign jurisdictions may indirectly affect our operations.

We conduct our manufacturing operations in South Africa and sell our products internationally. Although we do not have direct sales, operations, or customers in regions experiencing significant instability, such as Venezuela, recent labor strikes, political instability, and economic conditions in Venezuela may contribute to broader regional or global disruptions, including impacts on international trade relationships, energy markets, currency volatility, or global logistics networks.

In addition, changes in diplomatic relationships, foreign policy positions, or international regulatory frameworks involving countries experiencing political or economic instability could result in new or expanded trade restrictions, sanctions, compliance obligations, or logistical challenges imposed by foreign governments, including the United States. Such developments could indirectly affect the availability or cost of certain inputs, transportation services, or third-party suppliers upon which we rely.

While we believe our current supply chain and manufacturing operations are diversified and resilient, we cannot assure investors that future geopolitical developments will not result in increased costs, delays, or other adverse effects on our business, financial condition, or results of operations.

Risks Related to International Military Activity and Geopolitical Developments

Military activities, including joint military exercises conducted by governments, may contribute to geopolitical uncertainty and could indirectly affect global business conditions.

South Africa periodically participates in joint military exercises and other defence-related activities with foreign governments, such as recent exercises with Russia and China. While such activities are not directed at our business and we are not involved in any military or defence operations, heightened geopolitical activity or increased international tensions arising from military cooperation or exercises may contribute to broader uncertainty in global markets.

Such developments could result in changes to international relations, trade policies, regulatory requirements, or market conditions, including potential impacts on currency volatility, transportation logistics, or cross-border commerce. For example, these activities have drawn criticism from Western governments, potentially straining South Africa’s relations with key trading partners like the United States and leading to tariffs, sanctions, or restrictions on market access (as evidenced by the recent 30% U.S. tariff on South African imports).

Although we believe our manufacturing operations and supply chain are appropriately structured to manage normal geopolitical risks, we cannot assure investors that increased geopolitical tensions or related policy responses will not result in higher costs, delays, or other adverse effects on our operations, financial condition, or results of operations.

These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties, and other factors, many of which are beyond our control, that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" (including the potential adverse impacts of the 30% U.S. tariff on South African imports), as well as our reliance on key distributors (Note 2(n)), foreign currency fluctuations (Note 2(b)), regulatory approval delays for new products (e.g., FDA 510(k) processes), supply chain disruptions, competitive pressures in the medical device market, and general economic conditions affecting healthcare spending. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.

Financial Risks: We carry substantial debt, may need additional financing, and face exposure to interest rate changes, accounting rule shifts, and tax regulation updates, all of which could impact financial flexibility and results.

Operational Challenges: Our success depends on product development, supply chain continuity, and competitive positioning. Industry consolidation, pricing pressures, IT disruptions, and foreign exchange volatility pose risks to our operations and profitability.

Customer and Market Exposure: We rely heavily on a limited number of customers, including DISA Life Sciences, which increases the risk of revenue concentration. Inadequate insurance coverage and internal control weaknesses may further exacerbate operational vulnerabilities.

Management and Governance: Our business depends on a small number of key personnel, many of whom are located outside the U.S. Concentrated voting power among founders and limited public-company experience heighten governance and compliance risks.

Regulatory and Legal: Delays in obtaining regulatory approvals, potential product liability, compliance with marketing and reimbursement rules, IP protection, and evolving environmental and data privacy laws all pose significant risks. Violations could lead to penalties or legal action.

Geopolitical and Regional Risks: Political and economic instability in South Africa—such as load-shedding, exchange controls, and FATF grey-listing—may impair operations. Broader geopolitical tensions and trade disputes also affect supply chains and market access. Geopolitical and trade risks due to tariffs and trade wars.

Market and Securities Risks: Our shares trade on the OTCQX market and are considered penny stocks, which may limit liquidity. Future equity issuances could dilute existing shareholders, and share prices may fluctuate significantly due to external factors.

Revenue Concentration Risk: We derive a substantial portion of our revenue from a single customer, DISA Life Sciences, which accounted for approximately 92% of our total revenue for the nine months ended November 30, 2025. Our financial results, cash flows, and operating performance are therefore significantly dependent on the continued business relationship with this customer. A reduction in purchases from, or the loss of, DISA Life Sciences could have a material adverse effect on our results of operations and financial condition. While we endeavor to diversify our customer base, we may not be able to replace this level of revenue in the near term. Investors should consider the potential impact of this customer concentration when evaluating our business and prospects.

Newly Imposed U.S. Tariff on South African Imports May Materially Impact Our U.S. Revenue and Profit Margins

On July 7, 2025, the President of the United States announced a 30% tariff on all goods imported from South Africa into the United States, effective August 1, 2025. This tariff was introduced unilaterally and is reportedly based on concerns over a perceived trade imbalance between the two nations. While the South African government has contested the rationale behind this action and initiated negotiations, there is currently no indication that the tariff will be lifted or reduced in the near term.

As a company that exports goods from South Africa into the United States, this tariff introduces a material cost burden to our U.S.-bound shipments. The U.S. tariff could increase cost of goods sold by 30% on approximately 5% of revenue from our Domestic Sales segment (Inside the United States), potentially reducing fiscal year gross margin by 1 to 2 percentage points if unmitigated. Unless mitigated through restructured pricing, supply chain adjustments, or diplomatic resolution, the tariff is likely to have an adverse effect on our gross margins, U.S. revenue, and overall profitability. In addition, the tariff may reduce our competitiveness in the U.S. market and lead to delayed or reduced purchase orders from our distributors and customers.

We are actively assessing the potential impact of the tariff on our operations and financial results and evaluating appropriate contingency strategies, including sourcing alternatives, pricing adjustments, and geographic diversification of revenue. However, there can be no assurance that these measures will be successful or that the tariff will not materially and adversely affect our financial condition and results of operations.

This list is not an exhaustive list of the factors that may affect any of our forward-looking statements. These and other factors should be considered carefully, including those contained in our Annual Report on Form 10-K under “Risk Factors” for the year ended February 28, 2025, and readers should not place undue reliance on our forward-looking statements. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made, and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Combined these companies now form the Medinotec Group of Companies.

The Company engages in in-house manufacturing for products that leverage its intellectual know-how, while also utilizing cash flows generated from marketing products as distribution partners with major players in the industry. This distribution business supports the cash flows of the internally developed products while a market is being established for these offerings. Our internally developed products include:

The Trachealator has changed the way that tracheal, and, to a degree, bronchial stenosis is managed in extremely ill patients. While there are multiple causes of tracheal stenosis, it is estimated that thousands of cases are reported every year. Multiple, safe, serial dilatations of the trachea are often curative and the Trachealator is currently in our management’s opinion the only device that is non-occlusive and which allows the procedure to be done with the patient fully awake and un-sedated.

The Trachealator received the CE Mark of approval by a European notifying body (DEKRA) in 2019. CE Marking is a qualification mandatory for any product to be sold in countries of the European Union but widely accepted by other countries in the Middle East, South American and Asian regions. The Trachealator is currently sold successfully in a large number of those countries.

In May of 2021 in recognition of the advancement in technology in the device, the Trachealator was awarded a Gold Medal in the Medical Design Excellence Awards The USA recognizes only an FDA approval to accept products into its market. This approval was obtained for the Trachealator in November 2021 through a 510(k) substantially equivalence process for Class II medical devices and sales has since commenced in the USA.

The medical device approval process differs for specific countries and territories in the world, and each may have additional requirements over and above CE mark and FDA. For example, Australia, Japan and China have their own quality accreditation systems (TGF, JIS & CFDA respectively) and do not accept CE marking and/or an FDA certificate. Applications for such accreditations will be considered to be made upon achieving a critical mass of sales in the USA & Europe.

This catheter could be used to post dilate the artificial valve in TAVI (Transcatheter Aortic Valve Implantation) without the need for pacing.

A clinical study was conducted in 2022, as part of the development of the Technical File documentation, which is currently undergoing examination by our Notified Body (DEKRA).

Submission for FDA certification via the 510(k) substantially equivalence process was made on May 31, 2024. FDA clearance was obtained on March 11, 2025. Management anticipates that OutFlo will be launched to the U.S. Market in Q4 of the 2026 financial year, while the product is already in market in South Africa.

A PTCA catheter is inserted either from the groin or the arm and threaded through the blood vessels, through the aorta into the heart. The cardiac surgeon and/or interventional cardiologist will move the catheter to the blocked artery (plaque). The balloon part of the catheter is inflated to open the blockage in the artery, after which the balloon is deflated, and the entire catheter withdrawn and removed. If this procedure is not effective enough to open the artery, a coronary stent will be placed inside the diseased area of the artery.

On the back of the Cape Cross, the Cape Cross NC Catheter was developed for post dilatation purposes. The product has become a mainstay of our cardiology range. It is CE Marked and widely used in South Africa. After a stent is placed in an artery, it is followed up by moving a NC catheter to the site where the stent was placed. The NC catheter balloon part is then inflated inside the stent. This is done to “seat” the stent inside the artery wall. In other words, if the stent was not optimally placed, the NC Catheter can be used to make the stent fit “snugly” against the artery wall to avoid dislodgement and movement of the stent after placement.